Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.38 |
| ▸ | FDPS | P14324 | 1/20 | 0.36 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.34 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.34 |
| ▸ | ABAT | P80404 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL998425 | 0.92 | PDE4B (0.59) | PDE4BALDH1A1TSHRPTPN1FDPS | |
| SCHEMBL667201 | 0.92 | ALDH1A1 (0.54) | PDE4BALDH1A1TSHRKDM4EPTPN1 | |
| SCHEMBL3362970 | 0.87 | PDE4B (0.42) | PDE4BALDH1A1KDM4EPTPN1ALDH1A3 | |
| SCHEMBL5863923 | 0.87 | PDE4B (0.47) | PDE4BALDH1A1TSHRKDM4EPTPN1 | |
| SCHEMBL10080332 | 0.87 | PDE4B (0.42) | PDE4BALDH1A1TSHRKDM4EPTPN1 | |
| SCHEMBL3594038 | 0.87 | PDE4B (0.64) | PDE4BALDH1A1TSHRKDM4EFDPS | |
| SCHEMBL2770227 | 0.85 | PDE4B (0.46) | PDE4BPTPN1PDE4D | |
| SCHEMBL16382600 | 0.84 | PDE4B (0.40) | PDE4BALDH1A1KDM4EPTPN1AOX1 | |
| SCHEMBL17754256 | 0.81 | PDE4B (0.49) | PDE4BALDH1A1KDM4EPTPN1PDE4D | |
| SCHEMBL8528712 | 0.81 | PDE4B (0.50) | PDE4BALDH1A1KDM4EPTPN1PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024231837-A1 | NEW BORON-BASED COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | UNIVERSITA' DEGLI STUDI DI TORINO (IT) | 2024-11-14 | — | — | WO | claimed |
| WO-2024231837-A1 | NEW BORON-BASED COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | UNIVERSITA' DEGLI STUDI DI TORINO (IT) | 2024-11-14 | — | — | WO | disclosed |
| EP-4277896-A1 | ANTI-QUORUM SENSING, ANTI-BIOFILM, AND INFLAMMATION ATTENUATING COMPOUNDS, COMPOSITIONS, AND METHODS OF USING SAME | B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University (IL) | 2023-11-22 | — | — | EP | disclosed |
| WO-2022153306-A1 | ANTI-QUORUM SENSING, ANTI-BIOFILM, AND INFLAMMATION ATTENUATING COMPOUNDS, COMPOSITIONS, AND METHODS OF USING SAME | B. G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNIVERSITY (IL) | 2022-07-21 | — | — | WO | disclosed |
| US-9139672-B2 | Polymerizable compound, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2015-09-22 | — | — | US | disclosed |
| US-9139672-B2 | Polymerizable compound, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2015-09-22 | — | — | US | disclosed |
| US-20140346399-A1 | POLYMERIZABLE COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2014-11-27 | — | — | US | disclosed |
| US-20140346399-A1 | POLYMERIZABLE COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2014-11-27 | — | — | US | disclosed |
| US-20130023567-A1 | Novel Compounds | SPEAR THERAPEUTICS LIMITED (GB) | 2013-01-24 | — | — | US | disclosed |
| US-8236827-B2 | Compounds | SPEAR THERAPEUTICS LIMITED (GB) | 2012-08-07 | — | — | US | disclosed |
| EP-0810201-A1 | PREVENTIVE/REMEDY FOR LIVER DISEASE | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1997-12-03 | — | — | EP | disclosed |
| EP-0466198-A1 | A lipoxygenase inhibitor | GREEN CROSS CORPORATION (JP) | 1992-01-15 | — | — | EP | disclosed |
| EP-0466197-A1 | A lipoxygenase inhibitor | GREEN CROSS CORPORATION (JP) | 1992-01-15 | — | — | EP | disclosed |
| EP-0464859-A1 | A lipoxygenase inhibitor | GREEN CROSS CORPORATION (JP) | 1992-01-08 | — | — | EP | disclosed |
| EP-0464858-A1 | A lipoxygenase inhibitor | GREEN CROSS CORPORATION (JP) | 1992-01-08 | — | — | EP | disclosed |
| US-4733002-A | Lipoxygenase inhibitor | GREEN CROSS CORPORATION (JP) | 1988-03-22 | — | — | US | disclosed |
| EP-0163270-A2 | A lipoxygenase inhibitor | GREEN CROSS CORPORATION (JP) | 1985-12-04 | — | — | EP | disclosed |
| US-4486602-A | GLUCOSIDASE UNHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1984-12-04 | — | — | US | disclosed |
| EP-0049981-B1 | VALIENAMINE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1984-07-25 | — | — | EP | disclosed |
| EP-0049981-A1 | Valienamine derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1982-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023567-A1 | Novel Compounds | MKI67, RB1, CCND1 | PDE4B 1903/4885ALDH1A1 1505/4885TSHR 799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.